The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.
Here is some other vaccine news of note for the week.
Samsung BioLogics is well on its way to becoming the world's largest contract manufacturer.
VBI-1501 showed neutralizing antibody activities against both fibroblast and epithelial cell infections.
Merck and international agencies are preparing to roll out the experimental vaccine, hoping to stifle a new wave of cases that has killed 19 people.
A yearlong struggle for control of Chinese vaccine maker Sinovac Biotech has forced the company to suspend manufacturing of its hepatitis A vaccine.
PaxVax picked up the FDA's fast track tag for its chikungunya vaccine.
Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.
Sanofi posted strong vaccines growth last year, but the first quarter of 2018 didn't deliver quite so well.